The question seems straightforward: does an AI agent that drafts Standard Operating Procedures in biopharma need its own account in the Quality Management System?

The answer is not as obvious as it seems — and the disagreement is more instructive than any single position.

The question

A straightforward scenario: a biopharma company wants to use an AI agent to draft SOPs — the detailed procedural documents that govern how everything from manufacturing to quality control gets done. The agent pulls from approved reference documents, company templates, and regulatory guidelines to generate a first draft that a human SME then reviews and finalizes.

Does that agent need its own login in the QMS?

The split

Here’s where the analysis lands:

“Yes, give it a service account” (2 answers): The AI needs a dedicated, traceable identity — a Non-Human Identity (NHI) or service account — with permissions limited to creating drafts only. This satisfies the ALCOA+ “Attributable” principle. If the AI acts under a human’s credentials, the audit trail falsely attributes the AI’s work to that human. That’s a data integrity violation.

One answer proposed a specific architecture: an API service account like SVC_SOP_Agent_v1.0, managed through the company’s IAM framework, with permissions to create draft records only — explicitly lacking the ability to review, approve, or execute any workflow step.

“No, treat it like a tool” (4 answers): The AI is no different from Microsoft Word or a spell-checker. You don’t give Word a QMS account. The human who invokes the AI is the responsible party. The AI’s involvement should be documented in supporting records or metadata, but the QMS audit trail begins and ends with the human.

One answer put it memorably: treat the AI as “the world’s fastest, most naive intern.” You’d never give your intern the keys to the QMS.

One answer presented both approaches, calling them “Direct QMS Integration” and “Air-Gapped Drafting” — acknowledging that the right architecture depends on the company’s validation maturity and risk appetite.

Where they all agreed

Despite the account question splitting opinion, every analysis converges on the same principles:

Human accountability is absolute. Every answer — unanimous — stated that a named human must own every SOP, review every AI-generated draft, and apply the final electronic signature. No answer suggested unsupervised AI output entering the QMS.

AI cannot sign or approve. Under 21 CFR Part 11 §11.50, electronic signatures must be linked to a specific individual. An AI is not an individual. This was a hard boundary in every answer.

Human-in-the-Loop is mandatory. The universal workflow:

AI generates draft → SME reviews line-by-line → Formal QMS approval cycle → Human e-signature

Hallucination controls are required. Every answer recommended constraining the AI with Retrieval-Augmented Generation (RAG) — pulling only from approved, version-controlled source documents. No answer suggested letting the AI loose on the open web to draft GxP procedures.

The AI tool itself needs validation. Whether it’s a GAMP 5 assessment, Computer Software Assurance (CSA), or a risk-based validation protocol, every answer agreed that an AI impacting GxP processes cannot escape the validation lifecycle.

The audit trail must capture AI involvement. Whether through a service account, metadata tags, or supporting documentation, every answer insisted that an auditor must be able to determine that AI was involved in creating the document.

What the regulations actually say (as of mid-2026)

The LLM answers were broadly correct on principles, but the regulatory landscape has moved faster than most of them captured.

FDA

The FDA published its draft guidance on AI in drug and biological product development in January 2025, introducing a risk-based credibility assessment framework. In September 2025 (updated February 2026), the agency finalized its Computer Software Assurance guidance — the modern validation paradigm that replaces rigid CSV with risk-based, critical-thinking approaches.

In January 2026, FDA and EMA jointly published 10 Guiding Principles of Good AI Practice (GxP-AI), signaling global convergence on AI governance expectations.

Most critically, the FDA issued its first AI-related warning letter in 2026 to a company that relied on AI agents to draft GMP-critical documents without adequate human review. The message was unambiguous: the Quality Unit remains responsible for CGMP compliance. Delegating oversight to an unvalidated algorithm is a violation of 21 CFR 211.22[c].

EU GMP Annex 22 — The game changer

On July 7, 2025, the European Commission, EMA, and PIC/S published a package of three interconnected documents:

  • Revised Annex 11 (Computerised Systems) — expanded from 5 to 19 pages with prescriptive rules on security, identity management, and audit trails
  • New Annex 22 (Artificial Intelligence) — the first dedicated GMP framework for AI/ML in pharmaceutical manufacturing
  • Revised Chapter 4 (Documentation) — formally codifying ALCOA++ (adding “Traceable” to the classic ALCOA+ framework)

Annex 22 is the document that settles the account debate — indirectly. It permits only static, deterministic machine learning models in critical GMP applications. Generative AI and large language models are explicitly excluded from critical use.

This means AI-assisted SOP drafting using LLMs is not a “critical application” under Annex 22, as long as the AI only drafts and a human approves. Which, in turn, means the validation burden is lower than many fear — and the air-gapped approach (AI outside the QMS, human brings content in) is the path of least regulatory resistance.

The consultation closed in October 2025. Final versions are expected mid-2026, with a typical 6-12 month grace period before enforcement. Because PIC/S co-authored the documents, these rules will land across 50+ participating authorities globally, not just the EU.

ISPE GAMP Guide: Artificial Intelligence

In July 2025, ISPE published a 290-page standalone guide for validating AI in GxP environments. It provides a risk-based lifecycle framework covering model drift, explainability, continuous monitoring, and change management — designed to work alongside GAMP 5 Second Edition. This is the practical handbook for companies trying to figure out how to validate their AI tools.

The architecture spectrum

The account debate maps to a spectrum of integration depth:

Integration Level Account Needed? Validation Burden Audit Trail
AI fully external (offline drafting) No Low (risk assessment) Human logs in; AI invisible to QMS
AI in pre-QMS staging area No Low-Medium Human copies content in; AI logs retained separately
AI embedded in eQMS platform Yes (service account) High (GAMP 5 / CSA) AI actions tagged distinctly in audit trail
AI as API integration to QMS Yes (service account) Medium-High API calls logged under service account

The DnXT Solutions team published a real-world implementation in May 2026: structural audit logging where AI-initiated actions are tagged with a distinct source identifier, service accounts map to named administrators, and a hard boundary prevents AI from generating SIGN or APPROVE audit records. It’s a compelling architecture — but as they acknowledge, “No regulatory authority has reviewed or endorsed this approach yet.”

The pragmatic answer for 2026

For most biopharma companies today, with Annex 22 still pending and CSA adoption underway, the safest path is:

Keep the AI outside the validated GxP boundary. Let it draft SOPs in a sandbox — a secure internal platform, a controlled staging environment, a dedicated workspace. A qualified human SME reviews the draft line-by-line, verifies every claim against source documents, and enters the final text into the QMS under their own credentials.

This gives you:

  • The efficiency gains of AI-assisted drafting (reports suggest 30-90% reductions in document cycle times)
  • Minimal validation scope — the AI is a drafting tool, not a validated computerized system
  • Clean audit trails — the QMS record starts with the human
  • Regulatory defensibility under both current FDA expectations and the incoming Annex 22 framework

As the regulatory landscape matures — post-Annex 22 finalization, post-FDA AI guidance finalization — the direct-integration approach with service accounts will become more standardized and defensible. Companies with the validation maturity and infrastructure to implement NHI management should start building that capability now. Everyone else should master the air-gapped approach first.

The seven non-negotiables

Regardless of which architecture you choose, these elements are non-negotiable:

  1. A named human owns every SOP. Full stop. The AI doesn’t own anything.
  2. AI output is always a draft. Never final. Never self-approving. Never bypassing the review cycle.
  3. Hallucination controls. RAG from approved sources. Template enforcement. Constrained system prompts. No open-web retrieval.
  4. Human review is rigorous. Line-by-line verification against source documents. Not rubber-stamping. Not “the AI is probably right.”
  5. AI tool governance. Change control for model updates, prompt changes, and vector database modifications. Each is a change control event.
  6. Audit trail completeness. AI involvement must be documented somewhere — in the QMS, in metadata, or in supporting records. An auditor must be able to ask “was AI involved?” and get a clear answer.
  7. An SOP for using AI. You need a procedure governing when and how AI tools are used, what they can and cannot do, and how their outputs are reviewed. An SOP for your SOP-writing AI.

The bigger picture

The regulatory world is converging on a consistent framework: AI is a tool, humans are accountable, and the audit trail must tell the whole story. The question of whether to give the AI a QMS account is ultimately a question about how much you want it inside your validated boundary. Both answers are defensible. What’s not defensible is having no answer at all.

The companies that will fare best in inspections are those that can clearly explain how AI fits into their quality system — not those that try to hide or minimize its use. Document your approach. Validate your tools. Train your reviewers. And when an inspector asks “who wrote this SOP?”, make sure the answer is a human who can be held accountable.

Sources: FDA Draft Guidance on AI in Drug Development (Jan 2025), FDA CSA Final Guidance (Sep 2025/Feb 2026), FDA-EMA GxP-AI Joint Principles (Jan 2026), EU GMP Annex 22 Draft (Jul 2025), ISPE GAMP Guide: Artificial Intelligence (Jul 2025), DnXT Solutions Part 11 Audit Trail Implementation (May 2026), IntuitionLabs GxP SOP Compliance Guide (Apr 2026), fdainspections.com Part 11 AI Guide (Sep 2025), MFLRC Annex 22 Analysis (2026).